Molecular Pathology Reimbursement: Outcome of the 2013 Medicare Gapfilling Process

30 October 2013

This webinar summarizes the outcome of the Medicare gapfilling process for 114 new molecular pathology (MoPath) codes that were implemented in 2013. The presentation addresses the final 2013 regional rates for these codes and the implications for national payment rates in 2014. We will discuss future changes in the molecular diagnostic reimbursement landscape and potential impact on clinical laboratories.

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.